Congress Asset Management Co. MA Sells 3,193 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Congress Asset Management Co. MA lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,825 shares of the medical equipment provider’s stock after selling 3,193 shares during the quarter. Congress Asset Management Co. MA’s holdings in Lantheus were worth $795,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clearbridge Investments LLC boosted its stake in shares of Lantheus by 45.4% in the 4th quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock valued at $33,404,000 after purchasing an additional 168,114 shares in the last quarter. South Dakota Investment Council boosted its stake in shares of Lantheus by 139.3% in the 4th quarter. South Dakota Investment Council now owns 27,317 shares of the medical equipment provider’s stock valued at $1,694,000 after purchasing an additional 15,900 shares in the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of Lantheus in the 4th quarter valued at $1,385,000. Boston Partners boosted its stake in shares of Lantheus by 9.6% in the 4th quarter. Boston Partners now owns 562,125 shares of the medical equipment provider’s stock valued at $34,344,000 after purchasing an additional 49,195 shares in the last quarter. Finally, Natixis Advisors L.P. boosted its stake in shares of Lantheus by 172.8% in the 3rd quarter. Natixis Advisors L.P. now owns 52,530 shares of the medical equipment provider’s stock valued at $3,649,000 after purchasing an additional 33,273 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. B. Riley upped their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Truist Financial upped their price target on shares of Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, JMP Securities reiterated a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.17.

Lantheus Stock Up 4.3 %

Shares of NASDAQ LNTH opened at $82.63 on Tuesday. The firm has a market capitalization of $5.73 billion, a PE ratio of 12.62 and a beta of 0.56. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $94.47. The firm’s 50-day moving average is $73.98 and its 200-day moving average is $65.49.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.11. The company had revenue of $369.98 million for the quarter, compared to analyst estimates of $349.46 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. Equities analysts expect that Lantheus Holdings, Inc. will post 6.51 EPS for the current year.

Insider Activity

In other news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Daniel Niedzwiecki sold 12,873 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total value of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares in the company, valued at approximately $6,408,285.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,269 shares of company stock valued at $2,557,300. 2.10% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.